Boston Scientific (NYSE:BSX) Issues Earnings Results

Key Points

• Boston Scientific reported Q1 adjusted EPS of $0.80 (vs. $0.79 consensus) and revenue of $5.20B (+11.6% YoY), but management trimmed Q2 guidance to $0.820–0.840 and FY‑2026 to $3.340–3.410, below Street expectations.
• The stock briefly rallied (~+6.7%) after the results, yet near‑term sentiment faces pressure from a large CEO share sale and multiple securities class‑action filings, even as institutional ownership is high (~89%) and the consensus price target remains $101.50.

Boston Scientific (NYSE:BSX - Get Free Report) issued its quarterly earnings results on Wednesday. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.01, FiscalAI reports. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The firm had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. During the same quarter in the previous year, the company posted $0.75 earnings per share. The company's revenue was up 11.6% compared to the same quarter last year. Boston Scientific updated its Q2 2026 guidance to 0.820-0.840 EPS and its FY 2026 guidance to 3.340-3.410 EPS.

Boston Scientific Trading Up 6.7%

Shares of BSX stock opened at $63.48 on Wednesday. The business has a 50-day moving average of $69.04 and a 200 day moving average of $86.31. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. Boston Scientific has a 1-year low of $59.38 and a 1-year high of $109.50. The stock has a market capitalization of $94.34 billion, a PE ratio of 32.28, a P/E/G ratio of 0.94 and a beta of 0.78.

Insiders Place Their Bets

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the business's stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.34% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in BSX. Maverick Capital Ltd. bought a new position in Boston Scientific in the fourth quarter worth about $280,735,000. Farallon Capital Management LLC boosted its position in Boston Scientific by 56.7% during the 4th quarter. Farallon Capital Management LLC now owns 7,439,564 shares of the medical equipment provider's stock valued at $709,362,000 after acquiring an additional 2,693,007 shares in the last quarter. Marshall Wace LLP grew its holdings in shares of Boston Scientific by 30.7% during the 3rd quarter. Marshall Wace LLP now owns 9,799,040 shares of the medical equipment provider's stock worth $956,680,000 after acquiring an additional 2,301,383 shares during the period. Morgan Stanley raised its position in shares of Boston Scientific by 10.8% in the 4th quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider's stock worth $2,189,289,000 after acquiring an additional 2,246,308 shares in the last quarter. Finally, Credit Agricole S A bought a new position in shares of Boston Scientific in the 3rd quarter worth approximately $204,812,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on BSX shares. Weiss Ratings cut Boston Scientific from a "buy (b-)" rating to a "hold (c+)" rating in a report on Wednesday, February 4th. Wall Street Zen cut shares of Boston Scientific from a "buy" rating to a "hold" rating in a research report on Saturday, March 28th. Argus raised shares of Boston Scientific to a "strong-buy" rating in a research note on Thursday, February 26th. BTIG Research restated a "buy" rating on shares of Boston Scientific in a report on Wednesday, February 4th. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $115.00 price objective on shares of Boston Scientific in a research note on Monday, March 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Boston Scientific has an average rating of "Moderate Buy" and a consensus price target of $101.50.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q1 results showed durable topline growth and a small EPS beat: net sales of $5.203B (up ~11.6% year/year) and adjusted EPS $0.80, slightly above consensus; GAAP net income rose sharply year over year — a signal that demand for core devices remains solid. Boston Scientific announces results for first quarter 2026
• Neutral Sentiment: Several sell‑side firms have adjusted models/price targets but many still rate BSX a Buy — analysts view the guidance cut as a potential reset that creates longer‑term upside if execution rebounds. Boston Scientific Stock Is Trending Today: What To Know Now
• Neutral Sentiment: Unusually high options activity (large call purchases) and elevated trading volume ahead of the print indicate traders positioned for volatility rather than a clear directional conviction; this can amplify intraday moves.
• Negative Sentiment: Management cut FY‑2026 and Q2 guidance: FY EPS guide of $3.340–3.410 vs. ~3.45 consensus and Q2 EPS guide of $0.820–0.840 vs. ~0.86 consensus; revenue outlook was lowered as well — the guidance miss/trim is the primary near‑term negative catalyst. Boston Scientific cuts 2026 profit forecast, trims revenue growth view
• Negative Sentiment: Multiple securities class‑action filings and investor‑notice campaigns (several law firms seeking lead plaintiffs; May 4 deadline) add headline/legal risk and can pressure sentiment and float until resolved. BSX Investor Alert: Securities Fraud Lawsuit
• Negative Sentiment: Recent reports of meaningful insider and institutional selling, plus prior analyst downgrades/target trims, increase near‑term supply pressure and reduce confidence until management demonstrates rehabbed guidance/trajectory.

About Boston Scientific

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.